NO FEE Inflection Biosciences JB4

16 Apr 2018

Share on FacebookTweet about this on TwitterShare on LinkedInShare on Google+Pin on PinterestShare on RedditEmail this to someone

Share on FacebookTweet about this on TwitterShare on LinkedInShare on Google+Pin on PinterestShare on RedditEmail this to someone

No Fee Pic
Pic Julien Behal Photography
RCSI and Inflection Biosciences enter research collaboration to target therapy-resistant breast cancer
Dublin, Ireland, November 23, 2017 – Pictured at the announcement of a research collaboration between RCSI and Inflection Biosciences that will target therapy-resistant breast cancer are (R) Dr Michael O’Neill, Director of Research and Development at Inflection Biosciences, Darren Cunningham, Chief Executive Officer at Inflection Biosciences Ltd and Professor Bryan Hennessy, Senior Clinical Lecturer at RCSI and Consultant Medical Oncologist (L) . The collaboration aims to understand why there can be resistance to major breast cancer therapies and examine potential new treatments by Inflection Biosciences for patients with a cancer that does not respond effectively to existing therapies.
Pic Julien Behal Phototgraphy
More info contact
Jane Butler BA mod, MA, MPRII
Senior Communications Officer
RCSI Communications
Royal College of Surgeons in Ireland
123 St. Stephen’s Green Dublin 2 Ireland
T: +353-(0)1-402-8610 M: +353-(0)87-753-1877
E: janebutler@rcsi.ie W: www.rcsi.ie

Inflection Biosciences and RCSI join forces to lead war on breast cancer

Editor John Kennedy is an award-winning technology journalist.

editorial@siliconrepublic.com